Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
37.67 USD | +0.78% | +7.05% | +75.05% |
15/05 | Spyre Therapeutics, Inc. Announces Board Changes | CI |
13/05 | Wells Fargo Adjusts Price Target on Spyre Therapeutics to $40 From $35, Maintains Overweight Rating | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+75.05% | 1.52B | |
+8.29% | 114B | |
+10.21% | 104B | |
+0.70% | 22.28B | |
-11.90% | 22.41B | |
-5.20% | 19.07B | |
-37.36% | 18B | |
-5.17% | 17.89B | |
+7.70% | 14.28B | |
+37.65% | 12.55B |
- Stock Market
- Equities
- SYRE Stock
- News Spyre Therapeutics, Inc.
- Baird Starts Spyre Therapeutics With Outperform Rating, $50 Price Target